Seeking more control over combos, Regeneron retakes full rights to cancer ‘backbone’ Libtayo

By buying back full rights to Libtayo from Sanofi, Regeneron believes it can better unlock the PD-1 inhibitor’s clinical and commercial potential, particularly in combinations including a pairing with the company’s own LAG3 inhibitor.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) will pay Sanofi (Euronext:SAN; NASDAQ:SNY) $900 million up front for full ownership of Libtayo cemiplimab-rwlc. The partners shared the oncology drug’s rights under a 2015 deal; Regeneron markets it in the U.S., and Sanofi elsewhere, and the partners split global profits equally...